Author

M. Ciorba

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:clinical cohort / trial· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

, J. G. Jacqueline G. Perrigoue· 1 shared A. Srivastava· 1 shared B. Claggett· 1 shared B. P. Abraham· 1 shared B. Shen· 1 shared C.-R. Shyu· 1 shared E. M. Davis· 1 shared E. Yee· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

, J. G. Jacqueline G. Perrigoue

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugs

K. N. Suvilesh, Y. Manjunath, Y. I. Nussbaum, M. Gadelkarim, A. Srivastava, G. Li, W. C. Warren, C.-R. Shyu, F. Gao, M. Ciorba, J. B. Mitchem, S. Rachagani, J. T. Kaifi

This study develops patient-derived tumor organoids from non-metastatic NSCLC tumors to test drug responses and identify chemoresistance mechanisms, finding 50% of organoids were chemo-resistant and could be sensitized by repurposed drugs.

bioRxiv · Oct 18, 2023 · PreprintCancer Biology

Epithelial cell biomarkers are predictive of response to biologic agents in Crohn's disease

M. Osterman, K. VanDussen, I. O. Gordon, E. M. Davis, K. Li, K. Simpson, M. Ciorba, B. P. Abraham, X. Guo, E. Yee, F. Allard, , J. G. Jacqueline G. Perrigoue, B. Claggett, B. Shen, T. S. Stappenbeck, J. J. Liu

The paper shows that ileal microvillar length (MVL) predicts response to biologics ustekinumab and vedolizumab in Crohn's disease, with combined biomarkers improving prediction accuracy.

bioRxiv · May 20, 2020Cell Biology